StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 576.38 Thousand USD | -25.74% |
| 2021 | 776.21 Thousand USD | -19.72% |
| 2020 | 966.85 Thousand USD | -17.56% |
| 2019 | 1.17 Million USD | -11.15% |
| 2018 | 1.31 Million USD | 16.81% |
| 2017 | 1.12 Million USD | 139.99% |
| 2016 | 470.84 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 3.86 Million USD | 10.05% |
| 2011 | 3.5 Million USD | -7.31% |
| 2010 | 3.78 Million USD | 41.59% |
| 2009 | 2.67 Million USD | 242.79% |
| 2008 | 779.94 Thousand USD | -54.09% |
| 2007 | 1.69 Million USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 88.29 Thousand USD | -56.13% |
| 2004 | 201.28 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 838.35 Thousand USD | 10.42% |
| 2024 Q1 | 759.26 Thousand USD | 0.0% |
| 2023 Q1 | 679.79 Thousand USD | 17.94% |
| 2023 Q2 | 710.39 Thousand USD | 4.5% |
| 2023 Q3 | 740.97 Thousand USD | 4.3% |
| 2022 Q2 | 727.16 Thousand USD | 2.26% |
| 2022 Q1 | 711.06 Thousand USD | -8.39% |
| 2022 FY | 576.38 Thousand USD | -25.74% |
| 2022 Q4 | 576.38 Thousand USD | -7.15% |
| 2022 Q3 | 620.76 Thousand USD | -14.63% |
| 2021 FY | 776.21 Thousand USD | -19.72% |
| 2021 Q4 | 776.21 Thousand USD | -2.3% |
| 2021 Q3 | 794.51 Thousand USD | -7.09% |
| 2021 Q2 | 855.14 Thousand USD | -6.27% |
| 2021 Q1 | 912.33 Thousand USD | -5.64% |
| 2020 Q4 | 966.85 Thousand USD | -7.73% |
| 2020 FY | 966.85 Thousand USD | -17.56% |
| 2020 Q1 | 1.12 Million USD | -4.16% |
| 2020 Q2 | 1.08 Million USD | -3.9% |
| 2020 Q3 | 1.04 Million USD | -3.0% |
| 2019 Q4 | 1.17 Million USD | -16.99% |
| 2019 Q2 | 1.77 Million USD | -20.7% |
| 2019 Q1 | 2.23 Million USD | 69.21% |
| 2019 Q3 | 1.41 Million USD | -20.23% |
| 2019 FY | 1.17 Million USD | -11.15% |
| 2018 Q4 | 1.31 Million USD | -52.57% |
| 2018 FY | 1.31 Million USD | 16.81% |
| 2018 Q1 | 1.1 Million USD | -1.87% |
| 2018 Q2 | 2.74 Million USD | 147.57% |
| 2018 Q3 | 2.78 Million USD | 1.38% |
| 2017 Q4 | 1.12 Million USD | -56.37% |
| 2017 Q3 | 2.58 Million USD | -1.74% |
| 2017 FY | 1.12 Million USD | 139.99% |
| 2017 Q1 | 2.39 Million USD | 407.71% |
| 2017 Q2 | 2.63 Million USD | 10.25% |
| 2016 Q1 | 1.93 Million USD | 0.0% |
| 2016 FY | 470.84 Thousand USD | 0.0% |
| 2016 Q4 | 470.84 Thousand USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q3 | 1.16 Million USD | 5.92% |
| 2013 Q1 | 1.09 Million USD | -71.62% |
| 2013 Q2 | 1.1 Million USD | 0.42% |
| 2013 Q4 | - USD | -100.0% |
| 2012 Q2 | 3.85 Million USD | 2.62% |
| 2012 Q3 | 4.16 Million USD | 8.11% |
| 2012 Q1 | 3.75 Million USD | 7.06% |
| 2012 Q4 | 3.86 Million USD | -7.35% |
| 2012 FY | 3.86 Million USD | 10.05% |
| 2011 FY | 3.5 Million USD | -7.31% |
| 2011 Q4 | 3.5 Million USD | 6.2% |
| 2011 Q1 | 4.26 Million USD | 12.59% |
| 2011 Q2 | 3.38 Million USD | -20.6% |
| 2011 Q3 | 3.3 Million USD | -2.37% |
| 2010 Q4 | 3.78 Million USD | 24.06% |
| 2010 FY | 3.78 Million USD | 41.59% |
| 2010 Q1 | 2.86 Million USD | 7.0% |
| 2010 Q2 | 2.87 Million USD | 0.57% |
| 2010 Q3 | 3.05 Million USD | 6.07% |
| 2009 Q2 | 2.26 Million USD | 13.16% |
| 2009 Q3 | 2.55 Million USD | 12.81% |
| 2009 FY | 2.67 Million USD | 242.79% |
| 2009 Q1 | 1.99 Million USD | 156.21% |
| 2009 Q4 | 2.67 Million USD | 4.81% |
| 2008 Q4 | 779.94 Thousand USD | 46.1% |
| 2008 FY | 779.94 Thousand USD | -54.09% |
| 2008 Q1 | 1.09 Million USD | -35.47% |
| 2008 Q2 | 965.88 Thousand USD | -11.89% |
| 2008 Q3 | 533.85 Thousand USD | -44.73% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | 1.69 Million USD | 0.0% |
| 2007 FY | 1.69 Million USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q1 | 55.78 Thousand USD | -36.82% |
| 2006 Q2 | 23.69 Thousand USD | -57.53% |
| 2006 Q3 | - USD | -100.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 Q2 | 142.3 Thousand USD | -17.5% |
| 2005 Q3 | 122.91 Thousand USD | -13.62% |
| 2005 Q4 | 88.29 Thousand USD | -28.17% |
| 2005 FY | 88.29 Thousand USD | -56.13% |
| 2005 Q1 | 172.48 Thousand USD | -14.31% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | 216.75 Thousand USD | 0.0% |
| 2004 Q4 | 201.28 Thousand USD | -7.13% |
| 2004 FY | 201.28 Thousand USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 6000.00 USD | -9506.367% |
| Arrayit Corporation | - USD | -Infinity% |
| Atlantic International Corp. | 1.29 Million USD | 55.578% |
| Biocept, Inc. | 10.37 Million USD | 94.445% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 51.3 Million USD | 98.877% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 61.22 Million USD | 99.059% |
| HTG Molecular Diagnostics, Inc. | 546.32 Thousand USD | -5.502% |
| iMD Companies, Inc. | 1.1 Million USD | 47.776% |
| IDenta Corp. | 428.17 Thousand USD | -34.613% |
| Interpace Biosciences, Inc. | 4.24 Million USD | 86.416% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | - USD | -Infinity% |
| Lumos Diagnostics Holdings Limited | - USD | -Infinity% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 278 Thousand USD | -107.332% |
| NovelStem International Corp. | 3.32 Million USD | 82.663% |
| Optigenex Inc. | 4.42 Million USD | 86.98% |
| PharmChem, Inc. | - USD | -Infinity% |
| Proteome Sciences plc | 1.63 Million USD | 64.661% |
| Response Genetics, Inc | 4.91 Million USD | 88.28% |
| Rennova Health, Inc. | 359.19 Thousand USD | -60.466% |
| RushNet, Inc. | 4.25 Million USD | 86.446% |
| ScreenPro Security Inc. | 249.05 Thousand USD | -131.432% |
| Stella Diagnostics Inc. | 798.44 Thousand USD | 27.812% |
| Todos Medical Ltd. | 33 Million USD | 98.253% |